Lv11
76 积分 2024-01-05 加入
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
2小时前
待确认
Metabolic challenges and interventions in CAR T cell therapy
3小时前
已完结
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria
29天前
已完结
Accelerating and optimising CAR T-cell manufacture to deliver better patient products
1个月前
已完结
IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study
1个月前
已完结
Small-molecule control of CAR T cells
1个月前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
2个月前
已完结
Inhibitory immune checkpoints in cancer immunotherapy
2个月前
已完结
Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL
3个月前
已完结
皖公网安备34019202002308
